The Court has left in place a ruling that revives the Plaintiff’s pay-for-delay dispute against drug makers GlaxoSmithKline and Teva. Read more
The all-cash settlement will be placed in an escrow account that the Plaintiffs recommended be administered by Citibank NA. Read more
The FTC has estimated that these deals cost Americans $3.5 billion annually in higher health care costs. Read more
A group of U.S. Senators has urged President Barack Obama to call for legislation banning so-called pay-for-delay deals among drugmakers that drive up prescription drug prices. Read more
The State of Alaska has won an important victory relating to the investigation of the drug maker Lupin by the state’s Attorney General. A Motion to Dismiss filed by the Attorney General’s of... Read more
A Massachusetts federal judge has given tentative approval to a $24 million settlement between Teva Pharmaceutical Industries Ltd. and class action Plaintiffs in a pay-for-delay case over ge... Read more
The California Supreme Court has ruled that the pay-for-delay pharmaceutical patent settlements can be challenged under state antitrust law. The appeals court revived claims by drug buyers t... Read more
U.S. District Judge Jan E. DuBois, a Pennsylvania federal judge, has folded Rite Aid Corp.’s pay-for-delay lawsuit against AbbVie Inc. and Teva Pharmaceuticals Industries Ltd. over Niaspan g... Read more
Lawyers at Beasley Allen have been researching a developing area of law for a little more than a year that deals with the intersection of Antitrust law and Patent law. The cases have gained... Read more
One of the Federal Trade Commission’s (FTC) top priorities in recent years has been to litigate a costly legal tactic that more and more branded drug manufacturers have been using to stifle... Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.